CoChat

Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass

Open access
Sakuma, Kunihiro, Yamaguchi, Akihiko · 2012 · Journal of Cachexia Sarcopenia and Muscle

The DOI matches its Crossref record; 259 of the 261 references it cites were found in a registry or an index.

Abstract

Recent advances in our understanding of the biology of muscle, and how anabolic and catabolic stimuli interact to control muscle mass and function, have led to new interest in the pharmacological treatment of muscle wasting. Loss of muscle occurs as a consequence of several chronic diseases (cachexia) as well as normal aging (sarcopenia). Although many negative regulators [Atrogin-1, muscle ring finger-1, nuclear factor-kappaB (NF-κB), myostatin, etc.] have been proposed to enhance protein degradation during both sarcopenia and cachexia, the adaptation of mediators markedly differs among these conditions. Sarcopenic and cachectic muscles have been demonstrated to be abundant in myostatin- and apoptosis-linked molecules. The ubiquitin-proteasome system (UPS) is activated during many different types of cachexia (cancer cachexia, cardiac heart failure, chronic obstructive pulmonary disease), but not many mediators of the UPS change during sarcopenia. NF-κB signaling is activated in cachectic, but not in sarcopenic, muscle. Some studies have indicated a change of autophagic signaling during both sarcopenia and cachexia, but the adaptation remains to be elucidated. This review provides an overview of the adaptive changes in negative regulators of muscle mass in both sarcopenia and cachexia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13539-011-0052-4

Cites

259 of 259 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Myostatin signals through the activin receptor IIB (Actr2b) ALK4/5 heterodimer activate Smad2/3 with the consequent nuclear translocation of Smad4 and blocking of MyoD transactivation in an autoregulatory feedback loop. In both sarcopenic and cachectic muscles, abundant activated Smad2/3 inhibit protein synthesis, probably due to blocking of the functional role of Akt. In sarcopenic muscle, Akt can block the nuclear translocation of FOXO to inhibit the expression of Atrogin-1. In contrast, the impaired regulation of FOXO by Akt results in the abundant expression of Atrogin-1 and the consequent protein degradation in cachectic muscle. Although the blood and muscle levels of TNF-α were increased in both muscle wasting, the elevation of NF-κB occurs in cachectic but not sarcopenic muscles. Both muscle wasting include the enhancement of apoptosis signaling. IGF-I insulin-like growth factor I, IGF-IR IGF-I receptor, PI3-K phosphatidylinositol 3-kinase, TORC1 component of TOR signaling complex 1, Rheb Ras homolog enriched in brain, mTOR mammalian target of rapamycin, eIF4E eukaryotic initiation factor 4E, FOXO forkhead box O, IKK inhibitor of κB kinase, NF-κB nuclear factor of kappa-B, MuRF1 muscle ring finger protein 1, TNF tumor necrosis factor
Fig. 1 Myostatin signals through the activin receptor IIB (Actr2b) ALK4/5 heterodimer activate Smad2/3 with the consequent nuclear translocation of Smad4 and blocking of MyoD transactivation in an autoregulatory feedback loop. In both sarcopenic and cachectic muscles, abundant activated Smad2/3 inhibit protein synthesis, probably due to blocking of the functional role of Akt. In sarcopenic muscle, Akt can block the nuclear translocation of FOXO to inhibit the expression of Atrogin-1. In contrast, the impaired regulation of FOXO by Akt results in the abundant expression of Atrogin-1 and the consequent protein degradation in cachectic muscle. Although the blood and muscle levels of TNF-α were increased in both muscle wasting, the elevation of NF-κB occurs in cachectic but not sarcopenic muscles. Both muscle wasting include the enhancement of apoptosis signaling. IGF-I insulin-like growth factor I, IGF-IR IGF-I receptor, PI3-K phosphatidylinositol 3-kinase, TORC1 component of TOR signaling complex 1, Rheb Ras homolog enriched in brain, mTOR mammalian target of rapamycin, eIF4E eukaryotic initiation factor 4E, FOXO forkhead box O, IKK inhibitor of κB kinase, NF-κB nuclear factor of kappa-B, MuRF1 muscle ring finger protein 1, TNF tumor necrosis factorCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 259 references

Research works printed but not linked: 3

  1. Roubenoff R Hughes VA Sarcopenia: current concepts J Gerontol A Biol Sci Med Sci 2000 55 M716 M724 10.1093/gerona/55.12.M716 11129393 · DOI · Paper page
  2. Sakuma K, Yamaguchi A (2011) Sarcopenia: molecular mechanisms and current therapeutic strategy. In: Perloft JW, Wong AH (eds) Cell aging. Nova Science, New York (in press)
  3. Moresi V Pristera A Scicchitano BM Molinaro M Teodori L Sassoon D Tumor necrosis factor-α inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response Stem Cells 2008 26 997 11008 10.1634/stemcells.2007-0493 18258721 · DOI · Paper page

Cited by

See all 164

Metadata

Authors
Sakuma, K., & Yamaguchi, A.
Affiliations
  • Toyohashi University of Technology (JP)
  • Health Sciences University of Hokkaido (JP)
Corresponding author
Sakuma, Kunihiro
Venue
Journal of Cachexia Sarcopenia and Muscle
Publisher
Wiley
Published
2012-01-12
Volume
3
Issue
2
Pages
77-94
ISSN
  • 2190-5991 (ISSN-L)
  • 2190-6009
OpenAlex
W2079792861
Cited by
137
References
261
Citations by year
2026: 2 · 2025: 12 · 2024: 7 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 5 · 2019: 6 · 2018: 11 · 2017: 11 · 2016: 7 · 2015: 11 · 2014: 15 · 2013: 21 · 2012: 3
FWCI
6.42
Type
journal article
Language
en
Open access
Locations
  • Journal of Cachexia Sarcopenia and Muscle (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (23500778)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
Keywords
sarcopenia, cachexia, muscle atrophy, skeletal muscle mass, atrogin-1, MuRF1, NF-κB signaling, myostatin, ubiquitin-proteasome system, apoptosis, autophagy, protein degradation, aging, cancer cachexia, heart failure, chronic obstructive pulmonary disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. https://app.cochat.ai/papers/10.1007/s13539-011-0052-4
The paper
Sakuma, K., & Yamaguchi, A. (2012). Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. Journal of Cachexia Sarcopenia and Muscle. https://doi.org/10.1007/s13539-011-0052-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.